Fmr LLC Sells 5,917 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Fmr LLC reduced its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 7.7% in the 3rd quarter, Holdings Channel reports. The firm owned 71,164 shares of the biopharmaceutical company’s stock after selling 5,917 shares during the quarter. Fmr LLC’s holdings in Esperion Therapeutics were worth $117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ESPR. Connor Clark & Lunn Investment Management Ltd. grew its stake in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 295,378 shares during the last quarter. Marshall Wace LLP raised its holdings in Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Esperion Therapeutics by 3,278.3% in the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after acquiring an additional 555,382 shares in the last quarter. XTX Topco Ltd raised its position in shares of Esperion Therapeutics by 751.6% during the second quarter. XTX Topco Ltd now owns 364,681 shares of the biopharmaceutical company’s stock worth $810,000 after purchasing an additional 321,859 shares during the period. Finally, Inspire Investing LLC acquired a new position in shares of Esperion Therapeutics in the second quarter valued at approximately $758,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Trading Up 0.9 %

ESPR opened at $2.19 on Monday. The company’s 50 day moving average is $2.42 and its 200-day moving average is $2.22. The company has a market cap of $431.51 million, a P/E ratio of -3.42 and a beta of 1.01. Esperion Therapeutics, Inc. has a 1-year low of $1.58 and a 1-year high of $3.94.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ESPR shares. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective on the stock. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, December 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Esperion Therapeutics currently has an average rating of “Hold” and an average price target of $7.30.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.